ImmunoGenesis data to be presented at SITC 2021

By The Science Advisory Board staff writers

November 3, 2021 -- Data from ImmunoGenesis will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting scheduled for November 10-14 in Washington, DC.

The following research titles will be presented:

  • "Human PD-L2 Triggers a Unique T Cell Inhibitory Program Through PD-1 Engagement Distinct Dual-Specific Antibodies Blocking Both PD-L1 and PD-L2 Engagement of PD-1 Restore Anti-Tumor Immunity"
  • "High-Potency Synthetic STING Agonists Rewire the Myeloid Stroma in the Tumor Microenvironment to Amplify Immune Checkpoint Blockade Efficacy in Refractory Pancreatic Ductal Adenocarcinoma"

  • "Intratumoral Delivery of High Potency STING Agonists Modulates the Immunosuppressive Myeloid Compartment and Induces Curative Responses in Checkpoint-Refractory Glioblastoma Models"
  • "Disrupted Oxygen Supply and Tumor Hyper-Oxygen Consumption Contribute Independently to Prostate Cancer Immune Privilege"
  • "Hypoxia Reduction in Tandem With Anti-Angiogenic Therapy Remodels the PDAC Microenvironment and Potentiates CD40 Agonist Therapy"
BioNTech to highlight clinical results from CAR T program
BioNTech plans to highlight new clinical data from a phase I/II trial of its BNT211 CAR T-cell therapy candidate at the Society for Immunotherapy of Cancer...
Immatics to highlight ACTengine program updates at SITC
Immatics plans to offer an update on its ACTengine IMA203 trial at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington,...
Incyte to showcase oncology portfolio at SITC
Incyte plans to highlight clinical study data for its oncology portfolio at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter